LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

ANI Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

82.02 0.06

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

80.88

Max

82.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

18M

27M

Verkäufe

16M

228M

KGV

Branchendurchschnitt

50.838

77.671

EPS

2.04

Gewinnspanne

11.684

Angestellte

897

EBITDA

19M

61M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+35.07% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-270M

1.8B

Vorheriger Eröffnungskurs

81.96

Vorheriger Schlusskurs

82.02

Nachrichtenstimmung

By Acuity

27%

73%

87 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

ANI Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2025, 22:02 UTC

Ergebnisse

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. Dez. 2025, 21:46 UTC

Ergebnisse

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. Dez. 2025, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. Dez. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. Dez. 2025, 23:20 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. Dez. 2025, 23:15 UTC

Ergebnisse

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. Dez. 2025, 22:59 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. Dez. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. Dez. 2025, 22:40 UTC

Ergebnisse

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. Dez. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 22:06 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. Dez. 2025, 22:02 UTC

Ergebnisse

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. Dez. 2025, 22:00 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. Dez. 2025, 21:53 UTC

Ergebnisse

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. Dez. 2025, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

10. Dez. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. Dez. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. Dez. 2025, 21:33 UTC

Ergebnisse

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. Dez. 2025, 21:32 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. Dez. 2025, 21:25 UTC

Ergebnisse

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. Dez. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. Dez. 2025, 21:16 UTC

Ergebnisse

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. Dez. 2025, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. Dez. 2025, 21:15 UTC

Ergebnisse

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. Dez. 2025, 21:14 UTC

Ergebnisse

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. Dez. 2025, 21:14 UTC

Ergebnisse

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer-Vergleich

Kursveränderung

ANI Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

35.07% Vorteil

12-Monats-Prognose

Durchschnitt 110.8 USD  35.07%

Hoch 121 USD

Tief 100 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ANI Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

70.05 / 71.85Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

87 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
help-icon Live chat